Creso Pharma secures agreement with UK-based Precision Healthcare: Share price up 6%

Creso Pharma Ltd (ASX: CPH) has announced this morning that it has secured a commercialisation agreement with UK-based Precision HealthCare Ltd to market and distribute Creso’s hemp-based human health nutraceuticals in the UK.

The launch of cannaQIX 10 and 50 is planned for the first quarter of 2018.

The business that Creso has partnered with, Precision Healthcare, is a private healthcare company which specialises in the development of consumer healthcare products. It is part of the Precision Marketing Group which sells and distributes consumer healthcare brands to mass retailers and independent pharmacies covering more than 5,000 points of sale in the UK.

The agreement covers the non-exclusive marketing and distribution of Creso’s products, targeting UK pharmacies and health food stores.

Creso describes cannaQIX as a unique standardised nutraceutical product, in a proprietary formulation, that contains full plant organic hemp extract with CBD, vitamins and zinc, aiming to reduce stress and to support mental and nervous functions in humans.

Creso announced that it has received confirmation for cannaQIX as a food supplement from the UK Trading Standard Office.

Swiss regulatory authorities have issued a certificate of free sales for the export of the product into the UK from Switzerland.

Creso CEO, Dr. Miri Halperin Wernli, said “We are delighted to partner with Precision Healthcare and to have obtained the necessary regulatory approval for cannaQIX in the UK – both significant milestones for our company”.

Precision Marking Group CEO, Matthew Caldwell-Nicholas said “We are very pleased to work with Creso Pharma…and we are looking forward to a successful business partnership.”

The Creso Pharma share price has rocketed up 6% at the open in reaction to this news. Creso will have to generate revenue and profit from this agreement in the long-term to justify its rise, but for now excitement is building about the agreements the company is making.

Don’t Buy A SINGLE Stock Until You Read This

While conflict overseas is all media talking-heads seem to mention these days, the billionaire founder of Tesla is losing sleep over what he sees as a far bigger threat.

Elon Musk Warns: This has “vastly more risk than North Korea”

If you missed your opportunity to get in on Google, Microsoft, or Amazon in their early days, don't let it happen again. This emerging technology trend could offer a second chance for anyone who wishes they took part in these millionaire-maker stocks.

Click here to discover more!

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.